Based on the white paper by Linda M. Pullan, Ph.D., “How to Win at the Partnering Game”
Biotech companies know that it’s essential to align with strategic partners to advance their drug candidates to market. But for the small biotech company the partnering process can sometimes be daunting. To help make the process easier, we’ve put together a list of the ten most common partnering myths. Avoid the mistakes based on these myths, and you’ll be well on your way to those hot licensing deals.
Myth #1: Later is Always Better
It would be logical to assume that the farther your drug is along the development path the more value you will get in a deal. But for the last five years both upfront payments and total deal values have been larger for deals done during Phase II than for deals done during Phase III.
Investors and partners typically do not determine value based on the stage of development as much as the answers to key efficacy questions, such as:
We’re excited about attending the upcoming Biotech Showcase™ in San Francisco, where we’ll be showcasing the many benefits of using ShareVault for biotech licensing deals and fundraising.
Mobile devices have quickly become an integral part of the workplace because, quite simply, they make employees more productive. Unfortunately, the security practices and budgets in most organizations are not keeping pace with the growing number of devices that must be managed and kept secured.
The challenge for today’s organizations is to effectively adopt a mobile strategy with technologies that enable the employee to work efficiently without putting confidential information at risk. However, one of the biggest barriers to achieving an effective mobile security strategy is employee resistance, making training and awareness programs essential components of any mobile strategy plan.
FireEye, a Silicon Valley security company, recently released a report shedding light on a new breed of criminals intent on using their hacking skills to gain a market edge in the pharmaceutical industry, where data on clinical trials, regulatory decisions or safety and legal issues can significantly affect a company’s stock price.
For more than a year, a group of cybercriminals, which Fire Eye has dubbed “Fin4” because they are one of several groups that hack for financial gain, has been pilfering email correspondence from more than 100 organizations—most of them publicly traded health care or pharmaceutical companies—apparently in pursuit of information significant enough to affect global financial markets.
By Steve Joseph
Vice President, Market Development, ShareVault
Biotechnology companies rely heavily on alliances with pharmaceutical companies to finance their research and development expenditures, and pharmaceutical firms rely heavily on alliances to supplement their internal research and development.And those partnerships are a good thing: Drugs that are jointly developed are more likely to advance in clinical trials than drugs that are developed by a single company. However, inexperienced biotech companies often receive substantially discounted payments when signing their first deal.
So, how do you know what your drug candidate is worth?
Join us and thousands of health technology innovators and decision makers at the LifeScience Alley Conference on November 19, 2014. Hear from world-renowned companies, providers and payors as they discuss the policies, business practices and advancements that are reinventing healthcare. It’s in Minneapolis!
We’ll be in booth 701, so please come by and say hello.
LifeScience Alley is the largest, state-based life science association in the country. Their 690+ member organizations come from all sectors of the life sciences ecosystem. The conference, which is celebrating 30 years of groundbreaking achievement and vision into the future of healthcare, is a great place to connect with like-minded companies, share insights and expertise, collaborate and forge partnerships.
To learn more visit www.lifesciencealley.org.
By John Badger,
Co-Founder and VP of Marketing & Product, ShareVault
Based on the webinar, The Seller’s Guide to M&A HR, by Brian Moriarty, VP of MADO (Mergers, Acquisitions, Divestitures & Outsourcing), Hewlett-Packard
Smart managers on both sides of a deal know that successful mergers are not just about financial wins, but are a result of merging the intellectual capital of both organizations. This means effectively channeling the skills and enthusiasm of employees and streamlining the way in which the new business operates so that it can rapidly overcome hurdles, clearly define new roles and capitalize on synergies.